Matches in Nanopublications for { ?s ?p "DDI between Tofacitinib and Certolizumab pegol - Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy. [drugbank_resource:DB08895_DB08904]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB08895_DB08904 label "DDI between Tofacitinib and Certolizumab pegol - Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy. [drugbank_resource:DB08895_DB08904]" assertion.